

KCNQ2 discovery and research: what do we know and where to go

Dr. Sarah Weckhuysen, MD, PhD

Neurogenetics Group, VIB-Department of Molecular Genetics University of Antwerp, Belgium

WHAT IS EPILEPSY?




Epilepsy


Common

- Prevalence 4-8/1000
- Life time incidence 3%

Key symptom = seizures





Generalized seizure EEG







Normal neuronal function







Nature Reviews 2006






Epilepsy

Disturbance in balance excitatory / inhibitory forces





Causes of epilepsy



Idiopathic(Genetic)

Stroke

MR/CP

Head trauma

Brain tumor

Infection

Others

From: Annegers JF. The Epidemiology of epilepsy. In: Elaine Wyllie. The Treatment of Epilepsy.



Genes linked to epilepsy

ALG13	GABRG2	PLCBI
ARHGEF9	GRIN2A	PRRT2
ARX	GRIN2B	PNKP
ATPIA2	HCNI	SCNIA
CDKL5	KCNJH	SCNIB
CHD2	KCNQ2	SCN2A
CHRNA4	KCNQ3	SCN8A
CHRNB2	KCNMAI	SLC25A22
CHRNA2	KCNTI	SLC2A1
DEPDC5	LGH	SPTANI
FOXGI	MEF2C	STXBPI
GABRAI	NRXI	SYNGAPI
GABRB3	PCDH19	TBCID24
	lon channel genes	

DISCOVERY OF KCNQ2 IN EPILEPSY

0


Voltage gated potassium channels

- Humans: > 70 potassium channel genes
- Small family of voltage gated KCNQ genes: KCNQ1-5
 - KCNQI: cardiac arrythmia
 - KCNQ2/3: epilepsy
 - KCNQ4: deafness




KCNQ2


- Encoding voltage gated potassium channel subunit K_v7.2
 - Hyperpolarisation
 - Stabilizes neuronal excitability





Heteromeric KCNQ2/KCNQ3 channels





Front. Pharmacol., 23 March 2012

1998: KCNQ2 mutations in Benign Familial Neonatal Seizures (BFNS)

- Mostly familial
- Seizures onset between 2 8 days, remission within first months of life
- Investigations normal
- Psychomotor development normal

KCNQ2 and KCNQ3 in BFNS 100 NØ O benign familial neonatal convulsions

Ν

Q2

Q3

.

\$ splice

Q3

Q2

+ insertion

deletion

C

Where the story starts

- KCNQ2 screening offered for neonatal seizures in diagnostic unit
 - 2010: I patient: refractory seizures and psychomotor regression
- Literature
 - 4 case reports of patients with neonatal seizures and intellectual disability

(Dedek et al 2003, Borgatti et al 2004, Schmitt et al 2005, Steinlein et al. 2007)



Methods


- KCNQ2 and KCNQ3 screening in 80 patients with unexplained neonatal or early onset epileptic encephalopathy
 - Onset of seizures < 3 months
 - Slowing of psychomotor development
 - Metabolic screening normal
 - Imaging: no explanation
 - Genetic screening for relevant genes normal



Results

- No KCNQ3 mutations
- 7 novel KCNQ2 mutations in 8/80 patients (10%)
- Inheritance
 - Heterozygous
 - Almost all mutations de novo
 - I mosaic father with benign neonatal seizures





Ann Neurol. 2012 Jan;71(1):15-25. doi: 10.1002/ana.22644.

- -

KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy.

Weckhuysen S, Mandelstam S, Suls A, Audenaert D, Deconinck T, Claes LR, Deprez L, Smets K, Hristova D, Yordanova I, Jordanova A, Ceulemans B, Jansen A, Hasaerts D, Roelens F, Lagae L, Yendle S, Stanley T, Heron SE, Mulley JC, Berkovic SF, Scheffer IE, de Jonghe P.

Neurogenetics Group, VIB-Department of Molecular Genetics, University of Antwerp, Antwerp, Belgium.



Whole Exome Sequencing Identifies KCNQ2 Mutations in Ohtahara Syndrome

Hirotomo Saitsu, MD, PhD,¹ Mitsuhiro Kato, MD, PhD,² Ayaka Koide, MD, PhD,³ Tomohide Goto, MD, PhD,³ Takako Fujita, MD,⁴ Kiyomi Nishiyama, PhD,¹

Epilepsia. 2013 Jul;54(7):1282-7. doi: 10.1111/epi.12200. Epub 2013 Apr 26.

Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation.

Kato M, Yamagata T, Kubota M, Arai H, Yamashita S, Nakagawa T, Fujii T, Sugai K, Imai K, Uster T, Chitayat D, Weiss S, Kashii H, Kusano R, Matsumoto A, Nakamura K, Oyazato Y, Maeno M, Nishiyama K, Kodera H, Nakashima M, Tsurusaki Y, Miyake N, Saito K, Hayasaka K, Matsumoto N, Saitsu H.

Orphanet J Rare Dis. 2013 May 22;8:80. doi: 10.1186/1750-1172-8-80.

Similar early characteristics but variable neurological outcome of patients with a de novo mutation of KCNQ2.

Milh M, Boutry-Kryza N, Sutera-Sardo J, Mignot C, Auvin S, Lacoste C, Villeneuve N, Roubertie A, Heron B, Carneiro M, Kaminska A, Altuzarra C, Blanchard G, Ville D, Barthez MA, Heron D, Gras D, Afenjar A, Dorison N, Doummar D, Billette de Villemeur T, An I, Jacquette A, Charles P, Perrier J, Isidor B, Vercueil L, Chabrol B, Badens C, Lesca G, Villard L.

Neurology. 2013 Nov 5;81(19):1697-703. doi: 10.1212/01.wnl.0000435296.72400.a1. Epub 2013 Oct 9.

Extending the KCNQ2 encephalopathy spectrum: Clinical and neuroimaging findings in 17 patients.

Weckhuysen S, Ivanovic V, Hendrickx R, Van Coster R, Hjalgrim H, Møller RS, Grønborg S, Schoonjans AS, Ceulemans B, Heavin SB, Eltze C, Horvath R, Casara G, Pisano T, Giordano L, Rostasy K, Haberlandt E, Albrecht B, Bevot A, Benkel I, Syrbe S, Sheidley B, Guerrini R, Poduri A, Lemke JR, Mandelstam S, Scheffer I, Angriman M, Striano P, Marini C, Suls A, De Jonghe P; KCNQ2 Study Group.

Neurology. 2014 Jan 28;82(4):368-70. doi: 10.1212/WNL.0000000000000060. Epub 2013 Dec 26.

KCNQ2 encephalopathy: delineation of the electroclinical phenotype and treatment response.

Numis AL¹, Angriman M, Sullivan JE, Lewis AJ, Striano P, Nabbout R, Cilio MR.

• September 2014

- 62 patients with KCNQ2 encephalopathy described in literature
 - 44 different mutations

WHAT DO WE KNOW ALREADY?

CLINICAL PRESENTATION

KCNQ2 encephalopathy

- 10% of patients with neonatal epileptic encephalopathy of unknown etiology
- KCNQ2 encephalopathy mutations
 - Novel: not reported in BFNS
- Inheritance
 - de novo
 - I mosaic father with benign seizures

KCNQ2 encephalopathy

• Neonatal onset

I patient onset at 5 months


• Seizure type at onset

Motor seizures, prominent tonic component

Often autonomic features: apnea, desaturation, bradycardia

- Dramatic onset, multiple sz daily
- Abnormalities on EEG
- Range of severity of intellectual disability


• MECHANISM






Mechanism








Orhan et al., Annals of Neurology, 2014




Mechanism



5/7 mutations: dominant negative effect on channel function

Orhan et al., Annals of Neurology, 2014





Miceli et al., PNAS 2013



Mouse model of dominant negative mutation


Nat Neurosci. 2005 Jan;8(1):51-60. Epub 2004 Dec 19.

Conditional transgenic suppression of M channels in mouse brain reveals functions in neuronal excitability, resonance and behavior.

Peters HC¹, Hu H, Pongs O, Storm JF, Isbrandt D.

-Transgenic adult mice carrying dominant negative KCNQ2 mutation

- recurrent spontaneous seizures
- impaired spatial learning
- marked hyperactivity



• TREATMENT?

Sodium channel blockers

Epilepsia. 2013 Jul;54(7):1282-7. doi: 10.1111/epi.12200. Epub 2013 Apr 26.

Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation.

Kato M, Yamagata T, Kubota M, Arai H, Yamashita S, Nakagawa T, Fujii T, Sugai K, Imai K, Uster T, Chitayat D, Weiss S, Kashii H, Kusano R, Matsumoto A, Nakamura K, Oyazato Y, Maeno M, Nishiyama K, Kodera H, Nakashima M, Tsurusaki Y, Miyake N, Saito K, Hayasaka K, Matsumoto N, Saitsu H.

Neurology. 2013 Nov 5;81(19):1697-703. doi: 10.1212/01.wnl.0000435296.72400.a1. Epub 2013 Oct 9.


Extending the KCNQ2 encephalopathy spectrum: Clinical and neuroimaging findings in 17 patients.

Weckhuysen S, Ivanovic V, Hendrickx R, Van Coster R, Hjalgrim H, Møller RS, Grønborg S, Schoonjans AS, Ceulemans B, Heavin SB, Eltze C, Horvath R, Casara G, Pisano T, Giordano L, Rostasy K, Haberlandt E, Albrecht B, Bevot A, Benkel I, Syrbe S, Sheidley B, Guerrini R, Poduri A, Lemke JR, Mandelstam S, Scheffer I, Angriman M, Striano P, Marini C, Suls A, De Jonghe P; KCNQ2 Study Group.

Neurology. 2014 Jan 28;82(4):368-70. doi: 10.1212/WNL.0000000000000060. Epub 2013 Dec 26.

KCNQ2 encephalopathy: delineation of the electroclinical phenotype and treatment response.


Numis AL¹, Angriman M, Sullivan JE, Lewis AJ, Striano P, Nabbout R, Cilio MR.





Retigabine

- Mutations => loss of function
 - Potassium channel opener retigabine



Miceli et al, 2013



Retigabine

Neurology. 2013 Nov 5;81(19):1697-703. doi: 10.1212/01.wnl.0000435296.72400.a1. Epub 2013 Oct 9.

Extending the KCNQ2 encephalopathy spectrum: Clinical and neuroimaging findings in 17 patients.

Weckhuysen S, Ivanovic V, Hendrickx R, Van Coster R, Hjalgrim H, Møller RS, Grønborg S, Schoonjans AS, Ceulemans B, Heavin SB, Eltze C, Horvath R, Casara G, Pisano T, Giordano L, Rostasy K, Haberlandt E, Albrecht B, Bevot A, Benkel I, Syrbe S, Sheidley B, Guerrini R, Poduri A, Lemke JR, Mandelstam S, Scheffer I, Angriman M, Striano P, Marini C, Suls A, De Jonghe P; KCNQ2 Study Group.

ORIGIN OF INTELLECTUAL DISABILITY KCNQ2 ENCEPHALOPATHY



KCNQ2 encephalopathy

Clinical

• No strict correlation seizure severity – outcome

• Functional

Nat Neurosci. 2005 Jan;8(1):51-60. Epub 2004 Dec 19.

Conditional ransgenic suppression of M channels in mouse brain reveals functions in neuronal excitability, resonance and behavior.

Peters HC¹, Hu H, Pongs O, Storm JF, Isbrandt D.

- Infrequent seizures
- Impaired spatial learning

B. KCNQ2 IN EPILEPSY: FURTHER RESEARCH QUESTIONS

0

CLINICAL QUESTIONS



Clinical

- Range of age of onset?
- Additional clinical features?
 - Severe metabolic acidosis during prolonged seizures
 - Severe behavioral problems, irritability
 - Autistic features, hypersensitivity to noise
 - •
- Correlation seizure frequency/duration outcome?
- Treatment response to existing AED?
 - Effect on seizures + cognition
- Effect of newer potassium channel openers?

•••••



Patient Registries

- USA: Rational Intervention for KCNQ2 Epileptic Encephalopathy (RIKEE) patient database
- Europe: ad hoc
 - 23 additional non-reported European patients
 - 7 Belgium
 - 8 new mutations
 - 5 treated with RTG
 - Prospective trial?

FUNCTIONAL QUESTIONS



Functional


- What are the consequences of different KCNQ2 mutations
 - Potassium channel function
 - Excitability of neurons
 - Brain functioning
 - Brain structure
- Reversal of mutational effect
 - Retigabine and other drugs
 - Gene therapy
 - Time frame



Models


Oocytes

Heterologous expression of KCNQmutations in Oocytes






Fully-automated Oocyte two-voltage clamp system






Models

 Neurons <= induced Pluripotent Stem Cells (iPSC)



• (Animal models)







Neurogenetics group - epilepsy

- Rik Hendrickx
- Tine Deconinck
- Jolien Roovers
- Tania Djémié
- Katia Hardies
- Arvid Suls
- Peter De Jonghe

SPECIAL THANKS TO:

Parents and patients with KCNQ2 mutations

All collaborators and treating physicians of patients with *KCNQ2* mutations